
Kineta Presenting in Multiple Sessions at the Preclinical Immuno-oncology Online 2022
Kineta Presenting in Multiple Sessions at the Preclinical Immuno-oncology Online 2022 Seattle, WA — (May 18, 2022) Kineta, Inc., a clinical stage biotechnology company focused on the development of n ...

Kineta Unveils New Preclinical Data on its Anti-CD27 Agonist Lead Antibodies at AACR 2022
Kineta Unveils New Preclinical Data on its Anti-CD27 Agonist Lead Antibodies at AACR 2022 Seattle, WA — (April 13, 2022) Kineta, Inc., a clinical stage biotechnology company focused on the developmen ...

Kineta to Present Poster on Anti-CD27 Agonist Antibody Program at the AACR Annual Meeting 2022
Kineta to Present Poster on Anti-CD27 Agonist Antibody Program at the AACR Annual Meeting 2022 Seattle, WA — (March 21, 2022) Kineta, Inc., a clinical stage biotechnology company focused on the devel ...

Kineta Invited to Participate in the Cowen 42nd Annual Health Care Virtual Conference
Kineta Invited to Participate in the Cowen 42nd Annual Health Care Virtual Conference Seattle, WA — (February 24, 2021) Kineta, Inc., a clinical stage biotechnology company focused on the developmen ...

Kineta to Present on the Company’s Platform at the 6th Annual Tumor Models for Immuno-oncology Summit
Seattle, WA — (January 24, 2022) Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today an upcoming presentation at the 6 ...

Kineta to Present at the H.C. Wainwright Bioconnect Virtual Conference
Kineta to Present at the H.C. Wainwright Bioconnect Virtual Conference Seattle, WA — (January 11 , 2022) Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immun ...

Kineta Presented New Preclinical Data on its Anti-CD27 Agonist Antibody Program at the ESMO Immuno-oncology Congress 2021
Kineta Presented New Preclinical Data on its Anti-CD27 Agonist Antibody Program at the ESMO Immuno-oncology Congress 2021 Seattle, WA — (December 17, 2021) Kineta, Inc., a clinical stage biotechnolog ...

Kineta Presents Phase 1/2 Clinical Trial Design of KVA12.1 at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
Kineta Presents Phase 1/2 Clinical Trial Design of KVA12.1 at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting Anti-VISTA immunotherapy is being advanced in a range of solid tumors ...

Kineta Presented Compelling Preclinical Data on its New CD27 Antibody Program at the 2021 SITC Annual Meeting
Kineta Presented Compelling Preclinical Data on its New CD27 Antibody Program at the 2021 SITC Annual Meeting Seattle, WA — (November 16, 2021) Kineta, Inc., a clinical stage biotechnology company fo ...

A promising cancer immunotherapy target: Novel agonistic human antibodies against the human T-cell costimulatory receptor CD27
Thierry Guillaudeux, Phd, Chief Scientific Officer Society for Immunotherapy of Cancer (SITC) 36th Anniversary Annual Meeting | November 13, 2021